Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2-early breast cancer: a discrete choice survey study

被引:0
|
作者
Mayer, Erica L. [1 ]
Smith, Mary Lou [2 ]
Guerin, Annie [3 ]
Latremouille-Viau, Dominick [3 ]
Hazra, Nisha C. [4 ]
Meng, Yan [4 ]
Qu, Wendi [3 ]
Bellefleur, Remi [3 ]
Ganapathy, Vaidyanathan [5 ]
Santarsiero, Liz [5 ]
Morlock, Robert [6 ]
Lustberg, Maryam B. [7 ]
机构
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[2] Res Advocacy Network, Plano, TX USA
[3] Grp Anal Ltee, Montreal, PQ, Canada
[4] Anal Grp Inc, London, England
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] YourCareChoice, Ann Arbor, MI USA
[7] Smilow Canc Hosp Yale New Haven, New Haven, CT USA
关键词
Patient preference; CDK4/6; inhibitor; Early breast cancer; Discrete choice experiment; CONJOINT-ANALYSIS APPLICATIONS; ADJUVANT ENDOCRINE THERAPY; INTERIM ANALYSIS; OPEN-LABEL; HEALTH; PALBOCICLIB; ONCOLOGIST; REGIMENS; STAGE;
D O I
10.1007/s10549-025-07627-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeAdding CDK4/6 inhibitors (CDK4/6is) to endocrine therapy (ET) for HR+/HER2- early breast cancer (EBC) demonstrated statistically significant invasive disease-free survival (iDFS) benefits in monarchE (node positive, high risk, stage II/III) and NATALEE (select N0 and all macroscopic N1, stage II/III). This study evaluated patient preferences for EBC treatment attributes and how these may translate for CDK4/6i selection.MethodsA web-based discrete choice experiment survey was conducted among US-based adult women with self-reported stage II/III HR+/HER2- EBC. Eight attributes were included, informed by 14 qualitative interviews (to identify most relevant attributes), expert clinical input, and differentiating features between CDK4/6is: efficacy (5-year iDFS), adverse events (venous thromboembolic event [VTE], diarrhea, fatigue), number of blood tests, number of electrocardiograms (EKGs), treatment duration, and schedule. Participants selected scenarios that best reflected their preferences from 10 choice cards, each displaying a pair of hypothetical treatment profiles. A conditional logit regression model was used to estimate preference weights and relative importance (RI) of attributes.ResultsA total of 409 women participated. Patient preferences, from high to low RI, were higher efficacy, lower diarrhea risk, lower fatigue risk, shorter treatment duration, and lower VTE risk. Number of blood tests, number of EKGs, and treatment schedule were less important. Utility scores were higher for reconstructed treatment profiles that resembled ribociclib.ConclusionThis study demonstrated that patients prefer adjuvant treatment with higher efficacy and lower risk of adverse events. These data will aid shared decision-making when discussing the addition of CDK4/6is to adjuvant ET for eligible patients with HR+/HER2- EBC.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 50 条
  • [41] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [42] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Klapp, Vanessa
    Buque, Aitziber
    Bloy, Norma
    Sato, Ai
    Yamazaki, Takahiro
    Zhou, Xi Kathy
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    Petroni, Giulia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [43] Decision-making criteria for the choice of 1st line CDK4/6-inhibitor therapy for HR+/Her2-breast cancer in Germany: DECISIONext
    Grabher, Patricia
    Hormann, Nikolas
    Gust, Ronald
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 38 - 38
  • [44] Decision-making criteria for the choice of 1st line CDK4/6-inhibitor therapy for HR+/Her2-breast cancer in Germany: DECISIONext
    Finas, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S644 - S644
  • [45] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Vanessa Klapp
    Aitziber Buqué
    Norma Bloy
    Ai Sato
    Takahiro Yamazaki
    Xi Kathy Zhou
    Silvia C. Formenti
    Lorenzo Galluzzi
    Giulia Petroni
    Journal of Translational Medicine, 21
  • [46] Are We Prepared for the CDK4/6 Revolution With HR+/HER2- Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
    Azoz, Seyla
    Peters, Martin
    Jones, Graham
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
  • [47] Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2-breast cancer and glioblastoma multiforme
    Majeski, Hannah
    Chahal, Kirti
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Okano, Akinori
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+HER2-Early Breast Cancer
    Raheem, Farah
    Ofori, Henry
    Simpson, Lacey
    Shah, Vishal
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (11) : 1258 - 1266
  • [49] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [50] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 136 - 138